Cargando…

Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus

Status epilepticus that cannot be controlled with first- and second-line agents is called refractory status epilepticus (RSE), a condition that is associated with significant morbidity and mortality. Most experts agree that treatment of RSE necessitates the use of continuous infusion intravenous ane...

Descripción completa

Detalles Bibliográficos
Autores principales: Reznik, Michael E., Berger, Karen, Claassen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882483/
https://www.ncbi.nlm.nih.gov/pubmed/27213459
http://dx.doi.org/10.3390/jcm5050054
_version_ 1782434120038612992
author Reznik, Michael E.
Berger, Karen
Claassen, Jan
author_facet Reznik, Michael E.
Berger, Karen
Claassen, Jan
author_sort Reznik, Michael E.
collection PubMed
description Status epilepticus that cannot be controlled with first- and second-line agents is called refractory status epilepticus (RSE), a condition that is associated with significant morbidity and mortality. Most experts agree that treatment of RSE necessitates the use of continuous infusion intravenous anesthetic drugs such as midazolam, propofol, pentobarbital, thiopental, and ketamine, each of which has its own unique characteristics. This review compares the various anesthetic agents while providing an approach to their use in adult patients, along with possible associated complications.
format Online
Article
Text
id pubmed-4882483
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48824832016-05-27 Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus Reznik, Michael E. Berger, Karen Claassen, Jan J Clin Med Review Status epilepticus that cannot be controlled with first- and second-line agents is called refractory status epilepticus (RSE), a condition that is associated with significant morbidity and mortality. Most experts agree that treatment of RSE necessitates the use of continuous infusion intravenous anesthetic drugs such as midazolam, propofol, pentobarbital, thiopental, and ketamine, each of which has its own unique characteristics. This review compares the various anesthetic agents while providing an approach to their use in adult patients, along with possible associated complications. MDPI 2016-05-19 /pmc/articles/PMC4882483/ /pubmed/27213459 http://dx.doi.org/10.3390/jcm5050054 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reznik, Michael E.
Berger, Karen
Claassen, Jan
Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title_full Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title_fullStr Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title_full_unstemmed Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title_short Comparison of Intravenous Anesthetic Agents for the Treatment of Refractory Status Epilepticus
title_sort comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882483/
https://www.ncbi.nlm.nih.gov/pubmed/27213459
http://dx.doi.org/10.3390/jcm5050054
work_keys_str_mv AT reznikmichaele comparisonofintravenousanestheticagentsforthetreatmentofrefractorystatusepilepticus
AT bergerkaren comparisonofintravenousanestheticagentsforthetreatmentofrefractorystatusepilepticus
AT claassenjan comparisonofintravenousanestheticagentsforthetreatmentofrefractorystatusepilepticus